Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

Sam Altman and Arianna Huffington’s AI Health Revolution

by Team Lumida
July 9, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
Sam Altman and Arianna Huffington’s AI Health Revolution

Source: Decrypt

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  • OpenAI and Thrive Global launch Thrive AI Health to extend health spans.
  • AI health coach offers personalized advice using biometrics and lifestyle data.
  • Partnership focuses on health equity, targeting underserved populations.

What Happened?

OpenAI’s Sam Altman and Thrive Global’s Arianna Huffington announced the launch of Thrive AI Health, a new initiative aimed at revolutionizing healthcare using artificial intelligence. Thrive AI Health will develop an AI health coach offering personalized recommendations based on biometrics and lifestyle habits.

The platform will integrate Thrive’s behavior change methodology, focusing on microhabit changes. DeCarlos Love, a former Google executive, will lead as CEO. The Alice L. Walton Foundation supports this venture, and key partnerships include Stanford Medicine and the Rockefeller Neuroscience Institute.

Why It Matters?

AI in healthcare promises to address critical issues like chronic disease management and health equity. With 130 million Americans diagnosed with chronic conditions, Thrive AI Health aims to provide tailored health recommendations, potentially reducing the prevalence of chronic diseases and improving quality of life.

As Arianna Huffington emphasized, AI can democratize access to health benefits, similar to how the New Deal transformed physical infrastructure. By leveraging AI, Thrive AI Health could offer scalable, precise health interventions that human coaches cannot match.

What’s Next?

The inaugural team at Thrive AI Health is moving swiftly to customize and test the AI health coach. They plan to make the product available to Thrive Global’s employer base and expand through self-insured employers and pharmaceutical companies. As they scale, the focus will remain on maintaining robust privacy and security measures.

Partnerships with academic institutions will further aid in refining and validating the AI coach’s effectiveness. Investors and stakeholders should watch for how this platform could become integral to future health infrastructure, especially in underserved communities.

Source: Fortune Well
Tags: AI health coachArianna HuffingtonSam Altman
Previous Post

Bullish Bitcoin: Why Market Experts Predict a Major BTC Comeback

Next Post

Crackdown on Property Fraud Shakes $4.7 Trillion Real Estate Market

Recommended For You

Anthropic’s IPO Could Hand 300-Plus Investors a Windfall, With a $1.33 Trillion Valuation About 38% Above Its $965 Billion May Round

by Team Lumida
4 hours ago

Anthropic’s IPO, expected to value it at $1.33 trillion or more, is set to reward over 300 investors, from Spark and Menlo to Amazon and Alphabet.

Read more

Commerce Moves to Close the Offshore Data-Center Loophole for Chinese AI Firms and Requires Licenses for Chip Exports to Five Countries, Its First Policy Response to the Nvidia Scandal

by Team Lumida
4 hours ago

Commerce issued a rule curbing Chinese firms’ offshore access to Nvidia compute and requiring chip-export licenses for five higher-risk countries.

Read more

Trump Administration Plans to Name Nvidia, OpenAI and More Than Two Dozen AI Firms ‘National Champions’ as the BAI AI ETF Sits 33% Below Its June Record

by Team Lumida
12 hours ago
The AI Capex Machine Keeps Roaring — Nvidia’s Manufacturing Partner Hon Hai Crushes Estimates as Server Demand Drowns Out Recession Fears

The Trump administration plans to name more than two dozen AI firms, including Nvidia and OpenAI, US national champions, the WSJ reported.

Read more

OpenAI Launches ChatGPT Wallet With Amex, Mastercard and Visa, Letting ‘Dots’ Agents Buy for U.S. Pro Subscribers

by Team Lumida
3 days ago

OpenAI launched ChatGPT Wallet with American Express, Mastercard and Visa, letting its “dots” agents make purchases for U.S. Pro subscribers over 18.

Read more

OpenAI’s Quarterly Revenue Tops $10 Billion for the First Time, Up Nearly 50% in a Quarter, as Anthropic’s Growth Slows to About 47%

by Team Lumida
5 days ago

OpenAI’s third-quarter revenue hit $10 billion for the first time, up nearly 50% from the prior quarter, as Anthropic’s growth slowed, Bloomberg reports.

Read more

FDA Orders Vision-Loss Warnings on Every GLP-1 Drug After Trials Show NAION Rates of 6.4 vs. 3.8 per 100,000 Patient-Years

by Team Lumida
6 days ago
Bernie Sanders Pushes for Cheaper Wegovy: Can Novo Nordisk Resist?

The FDA will require all GLP-1 drugs, including Wegovy and Zepbound, to warn of a rare optic nerve condition that can cause sudden, permanent vision loss.

Read more

Anthropic Sets Its IPO Range at $70 to $78 for 825 Million Shares, Targeting a Nov. 19 Nasdaq Debut at Up to $1.405 Trillion

by Team Lumida
6 days ago

Anthropic will sell 825 million shares at $70 to $78, raising up to $64.35 billion, and plans to price Nov. 18 and begin trading on Nasdaq Nov. 19.

Read more

Anthropic’s Retracted Prospectus Flashed 867 Million Shares at $70 to $80 Each, a $69.3 Billion Raise, as the Claude Maker Readies IPO Marketing in a Nervous AI Market

by Team Lumida
6 days ago

A leaked, retracted Anthropic filing pointed to a $69.3 billion raise at $70 to $80 a share, just as the Claude maker prepares to market its IPO.

Read more

AI Data Center Builders Face a 2027 Rate Shock, as $13.4 Billion of Maturing Debt Could Cost at Least $380 Million More to Refinance

by Team Lumida
1 week ago

BloombergNEF says refinancing 2027 data center debt at current Treasury yields would lift rates 2.85 points, with $1 trillion due in five years.

Read more

Lilly’s Foundayo Pill Cuts Sleep Apnea Severity by 43.8% in a Late-Stage Trial, Setting Up an FDA Filing by Year-End

by Team Lumida
1 week ago

Eli Lilly’s Foundayo pill cut sleep apnea events by 21.1 an hour vs. 4.8 on placebo, and Lilly plans to seek U.S. approval by year-end.

Read more
Next Post
low angle photo of city high rise buildings during daytime

Crackdown on Property Fraud Shakes $4.7 Trillion Real Estate Market

Man on his Surface laptop at home with Christmas decorations around

AI PCs: The Future of Computing or Just Hype?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

a can of soda sitting on top of a green container

SEC vs. Binance: How Stricter Scrutiny Could Impact Your Investments

September 16, 2024

Longtime Chipotle Bull TD Cowen Moves to Hold With a Street-Low $32 Target as Fourth-Quarter Sales Soften

October 23, 2026

Banks Led by Morgan Stanley Shelve a Junk Bond Sale for a $15 Billion Anthropic-Tied Texas Data Center After the State Freezes New Projects

October 29, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018